BridgeBio Pharma BBIO Repayments of deferred royalty obligations
Repayments of deferred royalty obligations at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept bbio:PaymentOfDeferredRoyaltyObligation.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's repayments of deferred royalty obligations.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's repayments of deferred royalty obligations?
- BridgeBio Pharma (BBIO) reported repayments of deferred royalty obligations of $11.29M in Q1 2026.
- How has BridgeBio Pharma's repayments of deferred royalty obligations changed year-over-year?
- BridgeBio Pharma's repayments of deferred royalty obligations increased by 7742.4% year-over-year, from $144K to $11.29M.
- What does repayments of deferred royalty obligations mean?
- Cash paid to settle obligations related to future royalty payments.
- How do you interpret repayments of deferred royalty obligations?
- An increase indicates the company is successfully fulfilling its royalty-based financing agreements, potentially reducing future revenue sharing burdens.
- How does repayments of deferred royalty obligations compare across companies?
- Specific to biotech and pharma companies that use royalty monetization to fund R&D.